The market
2020/2534(RSP)
Emission Allocations Objection
2023/2768(RSP)
Paxlovid Marketing Objection
2023/2604(RSP)
Draft renewing the authorisation for the placing on the market of products containing, consisting of or produced from
2022/2930(RSP)
Draft authorising the placing on the market of products containing, consisting of or produced from genetically modified
2021/3057(RSP)
The extension of the approval periods of the active substances benfluralin, dimoxystrobin, fluazinam, flutolanil,
2021/2552(RSP)
Active Substances Approval Extension
2019/2826(RSP)